Matrix Metalloproteinases MMPs

Apo E, apolipoprotein E CAD, coronary artery disease FKN, fractalkine MHC, major histocompatibility complex MCP-1, monocyte chemoattractant protein 1 MMPs, matrix metalloproteinases NK, natural killer oxLDL, oxidized LDL RANTES, regulated on activation, normal T cell expressed and secreted VSMCs, vascular smooth muscle cells. 

SPLA2, secretory phospholipase A2 COX-2, inducible nitric oxide synthase iNOS, inducible nitric oxide synthase SOD, superoxide dismutase ICAM-1, intracellular adhesion molecule-1 VCAM-1, vascular adhesion molecule-1 TNF-a, tumor necrosis factor-a IL, interleukin and MMP, matrix metalloproteinases. 

Fig. 8.1 A schematic diagram illustrating the involvement of NF-k I in gpl20, ROS, NO, PG, IL-1/3 and TNF-a-mediated neurotoxicity. NMDA-R, N-Methyl-D-aspartate receptor, cPLA2, cytosolic phospholipase A2 lyso-PtdCho, lysophosphatidylcholine AA, arachidonic acid cAMP, cyclic adenosine monophosphate PKA, protein kinase A TNF-a, tumor necrosis factor-a TNF-a-R, TNF-a-receptor IL-1/8, interleukin-1 /3 IL-l/i-R, IL-1/8-receptor, IL-6, interleukin-6 MARK, mitogen-activated protein kinase NO, nitric oxide PG, prostaglandins EP-R, prostaglandin receptors NF-kB, nuclear factor-icB NF-kB-RE, nuclear factor-/cB-response element I/cB, inhibitory subunit of NF-icB HIV-1, human immunodeficiency virus type 1 gpl20, HIV-1 coat glycoprotein COX-2, cyclooxygenase-2 iNOS, inducible nitric oxide synthase SPLA2, secretory phospholipase A2 SOD, superoxide dismutase MMP, matrix metalloproteinase and VCAM-1, vascular adhesion molecule-1...

Abbreviations-. MMP, matrix metalloproteinase MT-MMP, membrane-type matrix metalloproteinase. ... 

Figure 13.1 Scheme of events leading to corneal ulceration. MMP, matrix metalloproteinase PMN, polymorphonuclear leukocyte. 

MMP = matrix metalloproteinase TIMP = tissue inhibitor of MMP LV = left ventricular. 

---